Consumer health company Kenvue recently introduced a dual-brand strategy to strengthen its portfolio for Electrolyte hydration … Kenvue’s Dual-Brand Strategy: ORSL™ vs. eRZL™ for Complete HydrationRead more
Antidepressant Overdose Death: What Doctors Need to Know About TCA Toxicity
The tragic death of a medical aspirant in Patna due to a suspected Antidepressant Overdose has … Antidepressant Overdose Death: What Doctors Need to Know About TCA ToxicityRead more
The Hidden Link: New Study Exposes Obesity’s Inflammation Trigger
Researchers have finally discovered the molecular cascade that links Obesity Inflammation to a host of health … The Hidden Link: New Study Exposes Obesity’s Inflammation TriggerRead more
Controversy Erupts: PIL Challenges -40 NEET-PG Cut-Off
The recent, drastic reduction of the NEET-PG cut-off marks for 2025 admissions has sparked significant legal … Controversy Erupts: PIL Challenges -40 NEET-PG Cut-OffRead more
AI Breakthrough: First-Trimester Scan for Fetal Brain Defects
Deep learning technology is transforming prenatal screening. A recent international study, AIRFRAME, focused on developing an … AI Breakthrough: First-Trimester Scan for Fetal Brain DefectsRead more
Unlock the RSNA Dataset: A New Era for AI Breast Cancer Detection
The Radiological Society of North America (RSNA) has released a significant open-source dataset from its Screening … Unlock the RSNA Dataset: A New Era for AI Breast Cancer DetectionRead more
Skip the Knife? 10-Year Data Backs Antibiotics for Appendicitis
The APPAC randomized clinical trial provides the first long-term data exceeding five years on non-operative management … Skip the Knife? 10-Year Data Backs Antibiotics for AppendicitisRead more
Overwhelming Urge to Move: An RLS Clinical Review for Doctors
Restless Legs Syndrome (RLS) is a pervasive, sleep-related movement disorder significantly impacting approximately 3% of US … Overwhelming Urge to Move: An RLS Clinical Review for DoctorsRead more
New Frontline Hope: Sacituzumab Govitecan + Pembrolizumab for Advanced TNBC
Sacituzumab Govitecan, when combined with pembrolizumab, offers a promising new frontline treatment for patients with PD-L1-positive, … New Frontline Hope: Sacituzumab Govitecan + Pembrolizumab for Advanced TNBCRead more
The Truth About Fitness: Why You Peak Around Age 35
A major 47-year Swedish longitudinal study uncovers when adult physical decline truly begins. Researchers found that … The Truth About Fitness: Why You Peak Around Age 35Read more